Dan Zandberg
Clinical trials sponsored by Dan Zandberg, explained in plain language.
-
Triple threat: vaccine, immunotherapy, and Chemo-Radiation take on HPV head and neck cancer
Disease control CompletedThis phase 2 trial tested a new approach for people with intermediate-risk HPV-related head and neck cancer. Participants received an HPV-16 vaccine (ISA101b) plus the immunotherapy drug pembrolizumab alongside standard chemoradiation. The goal was to see if this combination coul…
Phase: PHASE2 • Sponsor: Dan Zandberg • Aim: Disease control
Last updated Jun 23, 2026 11:59 UTC
-
Tailored drug combo tested for tough head and neck cancers
Disease control CompletedThis phase II trial tested a personalized approach for people with advanced head and neck cancer that had stopped responding to prior immunotherapy. Researchers used genetic testing to choose which drug to add to nivolumab—either relatlimab or ipilimumab. The study enrolled 20 pa…
Phase: PHASE2 • Sponsor: Dan Zandberg • Aim: Disease control
Last updated Jun 22, 2026 11:55 UTC
-
Cancer patients may not need lifelong immunotherapy, study suggests
Knowledge-focused CompletedThis study looked at people with advanced solid tumors (like lung, bladder, or melanoma) who had been on immunotherapy for one year and whose disease was stable. Half stopped treatment and half continued. The goal was to see if stopping early affected how long until the cancer pr…
Phase: PHASE3 • Sponsor: Dan Zandberg • Aim: Knowledge-focused
Last updated Jun 17, 2026 12:06 UTC